MedTrace Logo

KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks

NCT00085943 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 866

Last updated 2011-05-16

No results posted yet for this study

Summary

This study will compare the ability of fosamprenavir 700 mg with ritonavir 100 mg twice a day or lopinavir 400 mg with ritonavir 100 mg twice a day both combined with a fixed dose combination tablet of abacavir 600 mg and lamivudine 300 mg once a day to suppress virus levels of HIV to less than 400 copies/mL of blood. In addition we will study the safety and tolerability of these compounds over the 48 week study period in patients naive to anti-HIV therapy.

Conditions

  • HIV Infection
  • Infection, Human Immunodeficiency Virus

Interventions

DRUG

LEXIVA (GW433908)

DRUG

Ritonavir

DRUG

KALETRA

DRUG

EPIVIR

DRUG

Ziagen

DRUG

Abacavir/Lamivudine

DRUG

Fosamprenavir

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials, Pharm.D. · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-05-31

Countries

  • United States
  • Austria
  • Belgium
  • Canada
  • France
  • Germany
  • Italy
  • Latvia
  • Luxembourg
  • Poland
  • Portugal
  • Romania
  • Spain
  • Switzerland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00085943 on ClinicalTrials.gov